| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | 33.417 | 54.834 | 44.203 |
| Total Income - EUR | - | - | - | - | - | - | - | 33.417 | 54.870 | 44.205 |
| Total Expenses - EUR | - | - | - | - | - | - | - | 29.082 | 38.953 | 41.602 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | 4.335 | 15.917 | 2.603 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | 3.689 | 13.826 | 2.264 |
| Employees | - | - | - | - | - | - | - | 1 | 1 | 1 |
Check the financial reports for the company - Y22 Laboratories S.a.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | 0 | 0 | 1.607 |
| Current Assets | - | - | - | - | - | - | - | 25.505 | 45.190 | 47.149 |
| Inventories | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | - | 18.826 | 36.561 | 46.216 |
| Cash | - | - | - | - | - | - | - | 6.679 | 8.629 | 932 |
| Shareholders Funds | - | - | - | - | - | - | - | 21.939 | 35.699 | 37.763 |
| Social Capital | - | - | - | - | - | - | - | 18.250 | 18.195 | 18.093 |
| Debts | - | - | - | - | - | - | - | 3.566 | 9.491 | 10.992 |
| Income in Advance | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6209 - 6209" | |||||||||
| CAEN Financial Year |
6209
|
|||||||||
Comments - Y22 Laboratories S.a.